Optimized immunosuppression to prevent graft failure in renal transplant recipients with HLA antibodies (OuTSMART): a randomised controlled trial. (February 2023)

• Record Type: Journal Article
• Authors: Stringer, Dominic; Gardner, Leanne; Shaw, Olivia; Clarke, Brendan; Briggs, David; Worthington, Judith; Buckland, Matthew; Danzi, Guilherme; Hilton, Rachel; Picton, Michael; Thuraisingham, Raj; Borrows, Richard; Baker, Richard; McCullough, Keith; Stoves, John; Phanish, Mysore; Shah, Sapna; Shiu, Kin Yee; Walsh, Stephen B.; Ahmed, Aimun; Ayub, Waqar; Hegarty, Janet; Tinch-Taylor, Rose; Georgiou, Evangelos; Bidad, Natalie; Kılıç, Ayşenur; Moon, Zoe; Horne, Robert; McCrone, Paul; Kelly, Joanna; Murphy, Caroline; Peacock, Janet; Dorling, Anthony;
• Is Part Of: EClinicalMedicine. Volume 56(2023)
• Publication Date: 2023-02
• Subjects: Kidney transplantation -- HLA antibodies -- Optimised immunosuppression -- Stratified medicine -- Kidney allograft failure; Medicine -- Research -- Periodicals; Medical policy -- Periodicals; Clinical Medicine; Health Policy; Public Health; Medical policy; Medicine -- Research; Periodical; Electronic journals; Periodicals; 613
• DOI: 10.1016/j.eclinm.2022.101819
• Languages: English
• ISSNs: 2589-5370

Abstract

Summary: Background: 3% of kidney transplant recipients return to dialysis annually upon allograft failure. Development of antibodies (Ab) against human leukocyte antigens (HLA) is a validated prognostic biomarker of allograft failure. We tested whether screening for HLA Ab, combined with an intervention to improve adherence and optimization of immunosuppression could prevent allograft failure. Methods: Prospective, open-labelled randomised biomarker-based strategy (hybrid) trial in 13 UK transplant centres [EudraCT (2012-004308-36) and ISRCTN (46157828)]. Patients were randomly allocated (1:1) to unblinded or double-blinded arms and screened every 8 months. Unblinded HLA Ab+ patients were interviewed to encourage medication adherence and had tailored optimisation of Tacrolimus, Mycophenolate mofetil and Prednisolone. The primary outcome was time to graft failure in an intention to treat analysis. The trial had 80% power to detect a hazard ratio of 0.49 in donor specific antibody (DSA)+ patients. Findings: From 11/9/13 to 27/10/16, 5519 were screened for eligibility and 2037 randomised (1028 to unblinded care and 1009 to double blinded care). We identified 198 with DSA and 818 with non-DSA. Development of DSA, but not non-DSA was predictive of graft failure. HRs for graft failure in unblinded DSA+ and non-DSA+ groups were 1.54 (95% CI: 0.72 to 3.30) and 0.97 (0.54–1.74) respectively, providing no evidence of an intervention effect. Non-inferiority for the overall unblinded versus blinded comparison was not demonstrated as the upper confidence limit of the HR for graft failure exceeded 1.4 (1.02, 95% CI: 0.72 to 1.44). The only secondary endpoint reduced in the unblinded arm was biopsy-proven rejection. Interpretation: Intervention to improve adherence and optimize immunosuppression does not delay failure of renal transplants after development of DSA. Whilst DSA predicts increased risk of allograft failure, novel interventions are needed before screening can be used to direct therapy. Funding: The National Institute for Health Research Efficacy and Mechanism Evaluation programme grant (ref 11/100/34 ).